SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the subject of intense retail speculation, with traders debating whether its recent price action represents a speculative bubble or a long-term opportunity, leading to volatile swings and high trading volume. The community is sharply divided, with some investors aggressively buying dips in anticipation of future index inclusion while others are betting on a significant correction, labeling it an overhyped IPO.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor a high-stakes legal dispute with its partner, Nippon Shinyaku, ahead of a crucial August FDA decision for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively debating the impact of this litigation on commercialization rights while expressing optimism that strong clinical trial data will ultimately drive an approval and significant upside.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors debate its valuation and potential for a short squeeze, while also expressing significant frustration with management's communication and the stock's prolonged underperformance. The conversation is heavily focused on the company's rare disease gene therapy pipeline, the impact of recent clinical trial data, and speculation regarding a potential buyout.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as a significant short interest faces potential pressure following strong Phase 3 clinical data for its gene-editing candidate. The community is actively debating the likelihood of a major pharmaceutical buyout and the implications of recent capital raising activities on the stock's future trajectory.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as retail investors react to a combination of workforce restructuring, record-breaking trading volumes, and bullish anticipation for new revenue streams like AI-driven trading tools and prediction markets. Community members are actively debating the stock's potential for a breakout, with many focusing on the impact of increased platform engagement during major sporting and market events.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is seeing significant volatility following the FDA's recent recommendation for a randomized, sham-controlled study for its Huntington's disease therapy, which has sparked intense debate regarding regulatory transparency and the ethics of trial design. The community is actively discussing the potential for a leadership shift at the FDA, the possibility of international regulatory approvals, and whether the stock's valuation has become oversold relative to its cash position.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh conflicting visions for the company's future, with ongoing boardroom drama and proxy fighting clashing with community speculation regarding potential data center tenant deals. Market participants are intensely focused on unusual options activity and the strategic value of the firm's energy-infrastructure-heavy land holdings in Texas.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing significant momentum driven by growing interest in post-quantum cryptography (PQC) and the firm's strategic partnerships with major tech giants, which has intensified speculative interest from retail investors. Community discussions are heavily focused on a potential short squeeze due to the stock's low float and high institutional ownership, with many traders drawing parallels to other parabolic moves in the quantum computing sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intensified selling pressure as investors react to a formal shareholder lawsuit alleging undisclosed Azure growth slowdowns and ongoing concerns regarding the high capital expenditure required for AI infrastructure. The community is actively debating the stock's performance relative to other tech leaders, with many traders frustrated by the persistent daily downward price action and questioning the long-term ROI of the company's aggressive AI investment strategy.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as the community scrutinizes the company's regulatory path following the investor update that confirmed an NDA submission for AXPAXLI is planned for the fourth quarter of 2026. While some investors remain optimistic about the FDA-blessed single-trial approval pathway and potential M&A interest, others are expressing concern over the timeline and the stock's recent volatility, leading to intense debates between bulls betting on a long-term turnaround and bears questioning the strength of the clinical data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


capai138

capai138